VLDL-induced triglyceride accumulation in human macrophages is mediated by modulation of LPL lipolytic activity in the absence of change in LPL mass

Biochim Biophys Acta. 2003 Feb 20;1631(1):51-60. doi: 10.1016/s1388-1981(02)00355-4.

Abstract

Mixed dyslipidemia of phenotype IIB is characterized by elevated levels of very low density lipoprotein (VLDL)-1 and VLDL-2 subfractions and of low density lipoprotein (LDL), which are associated with premature formation of atherosclerotic plaques, characterized by the presence of lipid-rich macrophage foam cells. Lipoprotein lipase (LPL) is a key factor in mediating macrophage lipid accumulation and foam-cell formation from native VLDL particles. The action of macrophage-derived LPL in the induction of intracellular lipid accumulation from triglyceride-rich lipoprotein (TRL) subfractions (VLDL-1, VLDL-2) is, however, indeterminate, as is the potential role of VLDL-1 and VLDL-2 in modulating macrophage LPL expression. We evaluated the role of LPL in the interaction of type IIB VLDL-1 and VLDL-2 with human macrophages. Both VLDL-1 and VLDL-2 subfractions induced significant accumulation of triglyceride (9.8-fold, P<0.0001, and 4.8-fold, P<0.0001, respectively) and of free cholesterol content (1.4-fold, P<0.001, and 1.2-fold, P=0.02, respectively). Specific inhibition (90%) of the lipolytic activity of endogenous LPL by tetrahydrolipstatin (THL) in the presence of VLDL-1 or VLDL-2 resulted in marked reduction in cellular loading of both triglycerides (-89%, P=0.008, and -89%, P=0.015, respectively) and free cholesterol (-76%, P=0.02, and -55%, P=0.06 respectively). Furthermore, VLDL-1 and VLDL-2 induced marked increase in macrophage-derived LPL enzyme activity (+81%, P=0.002, and +45%, P=0.02), but did not modulate macrophage-derived LPL mRNA and protein expression; consequently, LPL specific activity was significantly increased from 1.6 mU/microg at baseline to 4.1 mU/microg (P=0.01) and 3.1 mU/microg (P=0.05), in the presence of VLDL-1 and VLDL-2, respectively. We conclude that type IIB VLDL-1 and VLDL-2 induce triglyceride accumulation in human monocyte-macrophages primarily via the lipolytic action of LPL, which may involve stabilization and activation of the macrophage-secreted enzyme, rather than via modulation of enzyme production.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cells, Cultured
  • Cholesterol / analysis
  • Cholesterol / metabolism
  • Cholesterol / pharmacology
  • Enzyme Activation
  • Enzyme Inhibitors / pharmacology
  • Foam Cells / metabolism
  • Humans
  • Hyperlipoproteinemia Type II / blood*
  • Lactones / pharmacology
  • Lipolysis
  • Lipoprotein Lipase / analysis
  • Lipoprotein Lipase / antagonists & inhibitors
  • Lipoprotein Lipase / metabolism*
  • Lipoproteins / pharmacology
  • Lipoproteins, VLDL / blood*
  • Lipoproteins, VLDL / chemistry
  • Lipoproteins, VLDL / isolation & purification
  • Macrophages / metabolism*
  • Orlistat
  • RNA, Messenger / analysis
  • Triglycerides / analysis
  • Triglycerides / metabolism

Substances

  • Enzyme Inhibitors
  • Lactones
  • Lipoproteins
  • Lipoproteins, VLDL
  • RNA, Messenger
  • Triglycerides
  • lipoprotein cholesterol
  • Orlistat
  • Cholesterol
  • Lipoprotein Lipase